Clinical Scorecard: Brief Treatment of Peripheral Blood Cell Products with Fas Ligand via a Closed Automated Processing System Significantly Diminishes Immune Cell Reactivity of the Graft Both In Vitro and In Vivo

At a Glance

Key Highlights

• FasL treatment of mobilized peripheral blood cells (MPBCs) reduces immune cell reactivity in vitro and in vivo.
• Selective apoptosis induced by FasL spares CD34+ hematopoietic stem cells, preserving engraftment potential.
• Closed automated cell processing system enables standardized, reproducible ex vivo FasL treatment of grafts.

Guideline-Based Recommendations

Diagnosis

• Identify patients requiring allogeneic HSCT for malignant or non-malignant hematological diseases.
• Assess risk of graft-versus-host disease and immune reactivity prior to transplantation.

Management

• Consider ex vivo incubation of G-CSF mobilized peripheral blood cells with hexameric FasL (100–400 ng/ml) for 2 hours at 37°C using a closed automated cell processing system.
• Replace plasma with incubation medium prior to FasL treatment and exchange with transplantation buffer post-treatment.
• Avoid systemic immunosuppressive regimens that attenuate engraftment and graft-versus-tumor effects.

Monitoring & Follow-up

• Evaluate immune cell subsets post-treatment to confirm selective apoptosis of T-cell subsets and APCs.
• Monitor engraftment success and immune reconstitution post-transplantation.
• Assess for signs of graft-versus-host disease and infection.

Risks

• Potential for incomplete elimination of alloreactive T cells if FasL treatment parameters are not optimized.
• Risk of infection due to immune modulation should be monitored.
• Ensure CD34+ cell viability is maintained to prevent graft failure.

Patient & Prescribing Data

Healthy donors providing G-CSF mobilized peripheral blood cells for allogeneic HSCT recipients

Brief ex vivo FasL treatment selectively induces apoptosis in donor immune cells responsible for GvHD without compromising CD34+ stem cell viability or engraftment potential, potentially improving transplant outcomes and reducing immune-mediated complications.

Clinical Best Practices

• Use a closed, automated cell processing system (e.g., Fresenius Kabi LOVO) to ensure sterility and reproducibility of FasL treatment.
• Perform plasma exchange with incubation medium prior to FasL exposure to optimize cell environment.
• Maintain incubation conditions at 37°C with 5% CO2 for 2 hours during FasL treatment.
• Post-treatment, exchange incubation medium with transplantation buffer containing PlasmaLyte A and 5% human albumin solution.
• Confirm CD34+ cell purity (>85%) and viability (>80%) before and after treatment.
• Monitor glutathione levels in CD34+ cells as a marker of redox potential and cell health.
• Avoid direct prolonged exposure of purified CD34+ cells to FasL to prevent potential cytotoxicity.

References

• Study on FasL treatment uncoupling GvHD and GvT effects
• Use of Fresenius Kabi LOVO automated cell processing system
• Glutathione measurement using FreSHTracer